Table 1.
Patient characteristics in Cohort 1 and Cohort 2.
| Clinical characteristics | Cohort 1 (no = 64) | Cohort 2 (no = 53) | p Value test |
|---|---|---|---|
| Sex—no. (%) | |||
| Male | 22 (34.4) | 13 (24.5) | Chi-Square: 0.2469 |
| Female | 42 (65.6) | 40 (75.5) | |
| Age—yr | |||
| Median | 67 | 63 | Wilcoxon: 0.0494 |
| Range | 35–89 | 26–87 | |
| ECOGa performance status — no. (%) | |||
| 0 | 15 (23.4) | 10 (18.9) | Fisher: 0.2204 |
| 1 | 49 (76.6) | 43 (81.1) | |
| Smoking status — no. (%) | |||
| Never smoked | 42 (65.6) | 42 (79.2) | Fisher: <0.0001 |
| Former smoker | 17 (26.6) | 1 (1.9) | |
| Current smoker | 5 (7.8) | 0 (0.0) | |
| Unknown | 0 (0.0) | 10 (18.9) | |
| Disease stage — no. (%) | |||
| IIIB | 12 (18.7) | 0 (0.0) | |
| IV | 52 (81.3) | 53 (100.0) | |
| Brain metastasis — no. (%) | |||
| No | 43 (67.2) | 26 (49.1) | Chi-Square: 0.6585 |
| Yes | 21 (32.8) | 27 (50.9) | |
| Bone metastasis— no. (%) | |||
| No | 40 (62.5) | 31 (58.5) | Chi-Square: 0.0472 |
| Yes | 24 (37.5) | 22 (41.5) | |
| Type of EGFR mutation— no. (%) | |||
| Exon 19 deletion | 44 (68.8) | 26 (49.1) | Fisher: 0.0551 |
| Leu858Arg | 18 (28.1) | 21 (39.6) | |
| Otherb | 2 (3.1) | 6 (11.3) | |
| Type of EGFR TKI— no. (%) | |||
| Erlotinib | 37 (57.8) | 46 (86.8) | |
| Gefitinib | 25 (39.1) | 7 (13.2) | |
| Afatinib | 2 (3.1) | 0 (0.0) | |
| Progression-free survival | |||
| Median—mo (CI 95%) | 14.1 (8.8–16.3) | 13.0 (10.7–17.8) | |
| Overall survival | |||
| Median—mo (CI 95%) | 26.7 (17.9–37.1) | 27.1 (22.8–29.9) | |
| Best response— no. (%) | |||
| Complete response | 3 (4.7) | 12 (22.6) | |
| Partial response | 39 (60.1) | 20 (37.7) | |
| Stable disease | 16 (25.8) | 18 (34.0) | |
| Progressive disease | 6 (9.4) | 3 (5.7) |
a
ECOG, Eastern Cooperative Oncology Group.
b
Other, Cohort 1 Leu861Glu, Gly719X; Cohort 2 L861Q (no = 2), exon 20 insertion (no = 3), S768I (no = 1); no, number; mo, months.